100Xfounder
Get Featured

Develop first-in-class therapies for millions of people whose daily lives are limited by allergies Biotech

About IgGenix

The Problem IgGenix addresses a core startup pain point: fragmented operations, slow decision cycles, and poor visibility across teams. Organizations in this market often rely on disconnected tools, which creates delays, revenue leakage, and inconsistent customer outcomes.

The Solution Develop first-in-class therapies for millions of people whose daily lives are limited by allergies Biotech In practice, IgGenix centralizes critical workflows, automates repetitive coordination, and gives operators a real-time system of record. This reduces manual overhead and improves execution quality at scale.

Why it's growing With the rise of shifting customer expectations, faster digital adoption, and demand for measurable ROI, IgGenix is positioned to capture sustained demand. Buyers now prioritize speed, reliability, and clear ROI, and the company aligns directly with those purchasing criteria.

Culture The team operates in a fast-paced environment focused on startup innovation, product velocity, and customer-centric execution. Their culture emphasizes ownership, experimentation, and measurable outcomes.

Why it Matters

IgGenix matters now because with the rise of shifting customer expectations, faster digital adoption, and demand for measurable ROI, IgGenix is positioned to capture sustained demand. Buyers now prioritize speed, reliability, and clear ROI, and the company aligns directly with those purchasing criteria.

Funding Snapshot

Total Funding: $40.00MLast Round: Series B Khosla Ventures, $40M Series B in 2023All Rounds: 1
  • Series BKhosla Ventures, $40M Series B in 2023

Hiring Roles

This company is actively hiring.

Open Roles

Meet the Founders

Tech Stack

AWSReactPythonPostgreSQL

Last updated: February 23, 2026

IgGenix intelligence brief

This profile combines core company context with linked founder, funding, and newsroom routes so readers can evaluate business momentum without switching across multiple tools. Use it as a baseline for comparing peers in the same industry and stage.

For deeper validation, pair this page with founder profile, company news coverage, and stage-based funding hubs to contextualize updates against wider market movement.

Related Companies

Alternatives in Startup with comparable market signals.

Discover Now

Newsroom and topic pages connected to IgGenix.

No company-specific newsroom stories available yet.

Contextual Research Links

Jump to country, industry, stage, startup taxonomy, and newsroom routes tied to this company.

Want to get featured on 100Xfounder?

Want your company featured with founder details and funding visibility? Start here.

FAQs About IgGenix

Common questions people ask about this profile.

What is IgGenix?

Develop first-in-class therapies for millions of people whose daily lives are limited by allergies Biotech

Who founded IgGenix?

IgGenix is associated with IgGenix Team on 100Xfounder.

Where is IgGenix located?

IgGenix is listed in San Francisco Bay Area, California, USA.

What stage is IgGenix in?

IgGenix is currently mapped to Series B. Funding context: Khosla Ventures, $40M Series B in 2023

What is the latest funding round of IgGenix?

IgGenix's latest tracked round is Series B Khosla Ventures, $40M Series B in 2023. Total tracked rounds: 1.

Is IgGenix hiring now?

IgGenix hiring status: Open Roles.

What technologies does IgGenix use?

IgGenix is associated with AWS, React, Python, and PostgreSQL.

Is IgGenix verified on 100Xfounder?

Yes. IgGenix is currently marked verified on 100Xfounder as of March 3, 2026.

How can users connect with IgGenix founders?

Users can open founder profiles, use listed company links, and track signal updates directly from the 100Xfounder directory.